SGLT2 inhibitors and cardiovascular outcomes in patients with multiple myeloma and concomitant type 2 diabetes mellitus
Leuk Lymphoma
.
2025 Jul 22:1-4.
doi: 10.1080/10428194.2025.2536681.
Online ahead of print.
Authors
Jia Yi Tan
1
,
Aravinthan Vignarajah
2
,
Yong Hao Yeo
3
,
Kok Hoe Chan
4
,
Mohammad Muhsin Chisti
5
,
Talal Hilal
6
Affiliations
1
Department of Medicine, New York Medical College at St. Michael Medical Center, Newark, NJ, USA.
2
Department of Medicine, Cleveland Clinic Fairview Hospital, Cleveland, OH, USA.
3
Department of Internal Medicine/Pediatrics, Corewell Health, Royal Oak, Michigan, USA.
4
Department of Hematology/Oncology, Charleston Area Medical Center, Charleston, West Virginia, USA.
5
Department of Hematology/Oncology, Corewell Health William Beaumont University Hospital, Royal Oak, MI.
6
Department of Hematology & Oncology, Mayo Clinic, Phoenix, AZ, USA.
PMID:
40694617
DOI:
10.1080/10428194.2025.2536681
No abstract available
Keywords:
Multiple myeloma; SGLT2; diabetes; hematology; oncology.